Hi I'm Kate, community lead for @OpenMedicineHQ. Open access and free for everyone.
New York, NY
Joined February 2017
- Tweets10.5K
- Following180
- Followers3K
- Likes78.1K
Kate Sears retweeted
So wonderful to finally meet @scserendipity1 in person. Really excited about the opportunity to collaborate on his fantastic initiative, @OpenMedInsights! @OpenMedKate
Kate Sears retweeted
Me too!
Great data. Practise changing and I suspect not just for melanoma
It’s been a great ESMO so far
Well done study chairs @YJanjigianMD and my good mate James Larkin ⭐️ @royalmarsdenNHS @ICR_London
All the staff @myESMO
Even bumped into one of my favourite people @DrSanjayPopat looking very dapper
Hopefully lung cancer Moderna vaccine next?
I am hopeful..
@GIMedOnc @amerseburger @StephenVLiu @CharuAggarwalMD
@DrSapnaPatel doing a sensational job leading the Melanoma and Skin track.. And such a lovely person ⭐️
@OpenMedKate @OpenMedInsights @OncBrothers @OncoAlert
RT @shilpaonc: The #ESMO26 Presidential Symposium is about to begin! 🔥
Super excited to hear the highly anticipated results of the VOLGA…
Kate Sears retweeted
Big science. Bold discoveries. Better cancer care! 🧬
Honored to be one of the NEJM Group Clinician-Guides for #ESMO26! Excited to join outstanding oncology colleagues to highlight the latest advances in cancer research and translate science into better patient care.
@NEJM @NEJMClinician
🤖 Made with AI
Kate Sears retweeted
The FDA has converted the accelerated approval of pembrolizumab (IV) or pembrolizumab and berahyaluronidase alfa-pmph (SC) to traditional approval for patients with previously treated unresectable or metastatic TMB-high solid tumors, with an updated threshold of ≥13 mutations/Mb.
Based on the phase 2 KEYNOTE-158 trial, this approval highlights the evolving role of TMB as a predictive biomarker for immunotherapy and the importance of refining biomarker thresholds based on clinical efficacy data.
Another important step in the convergence of precision medicine and immunotherapy.
Shared my perspectives with @CancerNetwrk ! @SylvesterCancer @GlopesMd @Latinamd @HemOncMiami
cancernetwork.com/view/fda-a…
🚨@FDADrugs provides traditional approval to embrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in unresectable or metastatic TMB-H solid tumors.
🔗cancernetwork.com/view/fda-a…
Kate Sears retweeted
And Katy is superb. Collegiate, smart and a great colleague.
@OpenMedKate @OpenMedInsights
Come join our team! Omaha is beautiful, the @BuffettCancer is incredible and we have so much momentum.
Kate Sears retweeted
Thrilled and honored to join @FoundationATCG as Chief Medical Officer. Grateful to the FMI leadership team for their trust and confidence and looking forward to this exciting new chapter and all we can accomplish together.
foundationmedicine.com/press…
Kate Sears retweeted
Finding a target is only the start.
Ahead of #ESMO26, 🧬🎯 ESCAT v2 grades the evidence for benefit and resistance.
What does this result change for the person sitting in front of us?
@Annals_Oncology @myESMO @BenWestphalen @GPentheroudakis @quimmateo @OncoAlert @OpenMedicineHQ @Larvol @tompowles1
Kate Sears retweeted
Proud to be part of @OncoAlert . With the wealth of data coming out of #ESMO26 its helpful to have some select studies to key in on. Instead of taking one persons list we put together a group list based on Delphi consensus rules.
Immunotherapy and vaccine therapies clearly stealing the show, although still room for next generation targeted therapies too!
🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬
From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract cancer, our faculty picked the must-know GI abstracts from Madrid 👇
#GICancer #CRCSM
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara , @pashtoonkasi
, @GillSharlene
Kate Sears retweeted
Sharing experiences and learning together...
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
How to start dermatologic prophylaxis before first dose, Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
Kate Sears retweeted
Ten abstracts that will shape lung cancer practice, picked by our faculty 🫁
Stand-outs for me: DeLLphi-305 moving tarlatamab into 1L maintenance, and the head-to-head KRAS G12C data in Krascendo 1. Do not skip DIAL either: it asks whether we can safely stop IO at 6 months 👇 #ESMO26 #LCSM #LungCancer
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
Kate Sears retweeted
⭐️ Open Medicine Algorithm Spotlight ⭐️
Locally advanced and metastatic Cutaneous Squamous Cell Carcinoma (cSCC) from @OmidHamidMD @angelesclinic:
myopenmedicine.com/algorithm…
Kate Sears retweeted
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
What a fantastic, practical and free resource for using Daraxonrasib! Even has a patient handout!!! Love it!
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
Very proud of @TheIACH satellite symposium at #ASH26
Please join us in-person or virtually.
apps.hematology.org/go/am26/…
apps.hematology.org/go/am26/…
@mvmateos @COMyCongress @NBahlis @ZamagniElena
Kate Sears retweeted
Getting ready for @myesmo #ESMO26?
Here are the top ten #LCSM presentations by @oncoalert
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
Kate Sears retweeted
Thanks Kate
Hope to see you in Madrid
Great algorithm. Very timely
@ArndtVogel @MyriamChalabi @OncoAlert @OncBrothers @UsuarezMD @Uromigos @VincentRK @JoshuaRichterMD
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…